Carilion Clinic | Research and Development
Status and phase
Conditions
Treatments
About
The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Confirmed PAH (WHO Group 1) classified by one of the following subgroups:
Baseline visit right heart catheterization (RHC) must also meet the following criteria:
On a stable dose of an endothelin receptor antagonist (ERA) and/or phosphodiesterase type 5 inhibitor (PDE-5i) or soluble guanylate cyclase stimulator (sGC) therapy or if treatment naïve, willing to take one of these medications in addition to study drug
REVEAL Lite 2 risk score ≤9
WHO FC II or III
6MWD >165 meters
Exclusion criteria
PAH-related Exclusion Criteria:
CardioMEMS-related Exclusion Criteria, if applicable:
NOTE: Other inclusion and exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
50 participants in 1 patient group
Loading...
Central trial contact
Mary Lou Tomson
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal